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Abstract
Mutations of the p62/Sequestosome 1 gene (p62/SQSTM1)
account for both sporadic and familial forms of Paget's disease
of bone (PDB). We originally described a methionine→valine
substitution at codon 404 (M404V) of exon 8, in the ubiquitin
protein-binding domain of p62/SQSTM1 gene in an Italian PDB
patient. The collection of data from the patient's pedigree
provided evidence for a familial form of PDB. Extension of the
genetic analysis to other relatives in this family demonstrated
segregation of the M404V mutation with the polyostotic PDB
phenotype and provided the identification of six asymptomatic
gene carriers. DNA for mutational analysis of the exon 8 coding
sequence was obtained from 22 subjects, 4 PDB patients and
18 clinically unaffected members. Of the five clinically
ascertained affected members of the family, four possessed the
M404V mutation and exhibited the polyostotic form of PDB,
except one patient with a single X-ray-assessed skeletal
localization and one with a polyostotic disease who had died
several years before the DNA analysis. By both reconstitution
and mutational analysis of the pedigree, six unaffected subjects
were shown to bear the M404V mutation, representing potential
asymptomatic gene carriers whose circulating levels of alkaline
phosphatase were recently assessed as still within the normal
range. Taken together, these results support a genotype–
phenotype correlation between the M404V mutation in the p62/
SQSTM1 gene and a polyostotic form of PDB in this family. The
high penetrance of the PDB trait in this family together with the
study of the asymptomatic gene carriers will allow us to confirm
the proposed genotype–phenotype correlation and to evaluate
the potential use of mutational analysis of the p62/SQSTM1
gene in the early detection of relatives at risk for PDB.
Introduction
Paget's disease of bone (PDB; Online Mendelian Inheritance
in Man (OMIM) entry no. 602080) is a metabolic bone disease
characterized by accelerated bone resorption followed by the
deposition of dense, chaotic bone matrix, affecting up to 3%
of individuals of Caucasian ancestry above the age of 55 years
[1]. Although PDB is genetically heterogeneous, in some famil-
ial cases of late onset PDB an autosomal dominant pattern of
inheritance has been reported [2-4]. Mutations of the p62/
sequestosome 1 (p62/SQSTM1) gene account for most of
the sporadic and familial forms of PDB [1-5], and exons 7 and
8, encoding the ubiquitin-binding-associated domain (UBA),
host a clustered mutational area [2-5]. p62 acts as a scaffold
protein in signalling pathways downstream of the interleukin-1,
tumour necrosis factor (TNF)-α and nerve growth factor recep-
tors [6].
In a recent paper we described an M404V mutation in the
UBA of the p62/SQSTM1 gene in an Italian population of
patients affected by PDB [5]. This mutation has also been
AP = alkaline phosphatase; NFκB = nuclear factor κB; PCR = polymerase chain reaction; PDB = Paget's disease of bone; RANK = receptor activator 
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confirmed in other ethnic groups [7-9]. For the Italian patient
carrying this A→G transition at exon 8 [5], collection of the
family history demonstrated a clear inheritance for PDB. DNA
analysis for the p62/SQSTM1 gene mutation was performed
in all affected familial members and in several unaffected sub-
jects, to evaluate the segregation of the M404V mutation with
the PDB phenotype and to detect potentially asymptomatic
gene carriers. Through this analysis we identified both a famil-
ial form of PDB, in which the M404V mutation segregates with
a polyostotic phenotype of the disorder, and several asympto-
matic gene carriers.
Materials and methods
Family recruitment and disease ascertainment
The Local Ethical Committee of the University of Florence
approved this study. The PDB female proband (III-1) was clin-
ically evaluated and genetically characterized as a carrier of a
novel M404V mutation at exon 8 of the p62/SQSTM1 gene
(Fig. 1) [5].
Through the family history a familial form of PDB (F01 pedi-
gree, Fig. 1) was ascertained. The four-generation family, orig-
inating from central Italy, consists of 37 living subjects (22
females and 15 males; age range 33 to 92 years) and 18
deceased individuals (11 males and 7 females; Fig. 1). Mem-
bers from generations I to III were farmers born and still living
in a rural environment, whereas fourth-generation individuals,
although born in the same environment as previous genera-
tions, moved to urban life after adolescence. Relevant clinical
information on affected and gene-carrier members of the F01
pedigree was collected; they are summarized in Table 1.
All available family members were asked to undergo DNA
mutational analysis and biochemical assessment after admin-
istration of an informed consent form.
No information was available on the first (I) generation (sub-
jects I-1, I-1.0 and I-2; Fig. 1).
In the second (II) generation (Fig. 1) blood samples for
genomic DNA evaluation were obtained from the only living
subject (patient II-6), a 92-year-old male, suffering from a
benign hyperplasia of the prostate (Table 1). Male subject II-3,
the father of a III-6 affected individual (Fig. 1), was referred to
as a carrier of multiple bone deformities and pain by living
members of the family, strongly suggesting the presence of
PDB disease in this individual. Figure 2a contributes to sus-
taining this hypothesis.
The proband III-1, in whom the M404V mutation was first
detected [5], belongs to the third (III) generation (Fig. 1).
Patient III-6 died because of an osteogenic sarcoma within or
in a Pagetic bone. This patient was diagnosed as being
affected by PDB at the age of 62 years because of the pres-
ence of bone pain, elevated serum alkaline phosphatase (AP)
activity and X-rays indicating typical PDB. Bone scintigraphy
showed signs of disease in the right pelvis, the right proximal
femur and left ribs IV and VIII. Three years after the diagnosis
of PDB, bone pain in the right pelvis increased markedly and a
Figure 1
Family pedigree (F01) Family pedigree (F01). The proband, III-1, is indicated by an arrow. Members of family with ascertained clinical evidence of Paget's disease of bone 
(PDB; III-1, III-3, III-6, III-12 and III-13) are represented by black symbols. Subjects strongly suspected to be affected by PDB, as reported by per-
sonal history in relatives (II-3, II-8 and II-10), are indicated by horizontal bar symbols. Relatives potentially mutant on the basis of pedigree reconstruc-
tion (II-1, II-2, II-7 and III-5) are represented by vertical bar symbols. Grey symbols identify individuals known to have the M404V mutation but whose 
PDB disease was not expressed; open symbols indicate subjects not exhibiting either the mutation or clinical evidence of PDB. Underlined numbers 
indicate individuals in whom a genetic test was performed. Question marks identify individuals whose clinical phenotype is not verifiable.Available online http://arthritis-research.com/content/7/6/R1289
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bone biopsy showed the presence of an osteogenic sarcoma
on the Pagetic bone already metastasized to the lungs. The
patient died at 65 years of age after surgical and chemothera-
peutic interventions, some years before DNA analysis was per-
formed on the F01 pedigree.
The ages of members from the fourth (IV) generation (IV-1, IV-
2, IV-3, IV-5, IV-6, IV-13, IV-14, IV-15 and IV-16) ranged from
41 to 53 years. Neither clinical nor biochemical abnormalities
suggestive of PDB are currently evident in this younger group
(Fig. 1, Table 1).
Evaluation of AP, measured by an autoanalyzer, has been per-
formed also in all the individuals undergoing mutational analy-
sis. The upper limit of the reference range is 120 units/l.
DNA extraction, PCR and mutational analysis
After administration of an informed consent form, peripheral
blood was obtained from 22 subjects: 4 PDB patients (III-1, III-
3, III-12 and III-13) and 18 clinically unaffected members (II-6,
III-7, III-8, III-9, III-10, III-14, III-18, III-19, III-20, IV-1, IV-2, IV-3,
IV-5, IV-6, IV-13, IV-14, IV-15 and IV-16) (Fig. 1, Table 1).
Genomic DNA was extracted from peripheral blood
leukocytes with the use of a microvolume extraction method,
QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany), in
accordance with the manufacturer's instructions.
Exon 8 of the p62/SQSTM1 gene was amplified by PCR (I-
Cycler; Bio-Rad Laboratories, Milan, Italy) using a couple of
primers located in the flanking intron: 5'-CAGTGTGGCCT-
GTGAGGAC-3'/5'-CAGTGAGCCTTGGGTCTCG-3'. For
each patient we used 0.1 µg of DNA, in a final buffer volume
Table 1
Available clinical and mutational data on affected patients and gene carriers of PDB
Pedigree number (sex) Age at clinical diagnosis or 
DNA evaluation; present 
age (years)
AP (U/l) PDB-related clinical finding Other relevant clinical data
II-3 (M)a Deceased Unknown Diffuse marked bone deformities 
(Fig. 2a)
Died at age 76 years from 
Alzheimer's disease
II-8 (F)a Deceased Unknown Bone deformities at both lower 
extremities
Died at age 52 years from colon-
rectal cancer; also had breast 
cancer
II-10 (F)a Deceased Unknown Multiple marked diffuse skeletal 
deformities
Died at age 92 years from unknown 
cause
III-1 (F)b 57; 65 357 Third lumbar vertebra, pelvis, right 
proximal femur
Alive
III-3 (F)b 53; 79 560 Pelvis, both tibias Alive. Apparently healthy
III-5 (M)a Not assessed Unknown Diffuse bone pain Died at age 80 years from unknown 
cause
III-6 (F)a 62; deceased 2,259 Right pelvis and proximal femur, IV 
and VIII left ribs
Died 12 years previously from 
osteogenic sarcoma on Pagetic 
bone (right pelvis)
III-12 (M)b 64; 82 380 Left hipc Alive. Benign prostate hyperplasia
III-13 (M)b 65; 83 610 T5, T10 and L4 vertebral bodies, 
sacrum, right tibia, right femur, right 
shoulder and collarbone
Alive. Allergy to pollen, hypertensive 
cardiopathy
IV-1 (F) 41 <120 None Alive, age 42, healthy
IV-13 (F) 53 <120 None Alive, hypertension, age 54
IV-14 (F) 41 <120 None Alive, age 42, lumbar–sacral discal 
hernia, goitre
IV-15 (M) 47 <120 None Alive, age 48 allergy to pollen
IV-16 (F) 48 <120 None Alive, age 49, allergy to pollen
The M404V mutation was ascertained in individuals listed in bold. The highest observed levels of alkaline phosphatase (AP) are reported for each 
affected subject; the normal range is less than 120 units/l. PDB, Paget's disease of bone.
aIndividuals strongly suspected to be potential PDB patients after careful reconstruction of the familial clinical history. bThese subjects received 
two treatment courses with oral risedronate (30 mg/day) for 3 months followed by a 112-day follow-up period without treatment [24]; complete 
normalization of serum AP levels and bone pain remission were observed in all these treated subjects. cTotal bone scintigraphy was not performed 
on this subject; the skeletal extent of PDB is on the basis of X-ray evaluations.Arthritis Research & Therapy    Vol 7 No 6    Falchetti et al.
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of 50 µl (67 mM Tris-HCl, 16.6 mM (NH4)SO4, 0.01% Tween
20, 1.5 mM MgCl2, 0.2 mM deoxyribonucleotides, each primer
at 0.2 µM and 1 unit of Polytaq (Polymed, Florence, Italy)).
Thirty PCR cycles were performed at 94°C for 30 s, 55°C for
30 s and 72°C for 1 min, after a first denaturing cycle at 94°C
for 3 min. A final extension cycle of 5 min was performed at
72°C.
PCR products were tested by 2% ethidium bromide-stained
agarose-gel electrophoresis, purified with a High Pure PCR
Product Purification Kit (Roche, Indianapolis, IN, USA) and
finally sequenced with a BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA).
The sequencing reaction consisted of 25 repeated cycles of
denaturation for 10 s at 96°C, annealing for 5 s at 55°C and
extension for 2 min at 60°C. The sequencing products were
purified with a DyeEx 2.0 Spin Kit (Qiagen GmbH, Hilden,
Germany) to remove the excess dye terminator. A 5 µl sample
of each purified sequence was then resuspended in 15 µl of
formamide and denatured for 2 min at 95°C. Analysis of the
forward and reverse sequences was performed on an ABI




Suspicion or diagnosis of PDB was based on description by
relatives, evidence of bone deformities and pain strongly sug-
gestive of PDB (II-3 (Fig. 2a), II-8 and II-10) and, when possi-
ble, direct evidence of elevated total AP, X-ray scanning and
bone scintigraphy (III-1, III-3 (Fig. 2b), III-6, III-12 and III-13; Fig.
1, Table 1).
After careful reconstitution of their clinical history, 12 subjects
(6 males and 6 females), of which 11 were living, were
reported to be the following: clinically ascertained as PDB
patients (III-1, III-3 (Fig. 2b), III-6, III-12 and III-13) with
increased circulating levels of AP (more than 120 units/l); pre-
sumably affected by PDB (II-3 (Fig. 2a), II-8 and II-10); and
potentially mutant (II-1, II-2, II-7 and III-5; Table 1).
In accordance with previously described criteria, all affected
members, clinically ascertained (III-1, III-3 (Fig. 2b), III-6, III-12
and III-13), exhibited polyostotic localization of PDB (III-1, III-3,
III-6 and III-13), except patient III-12 (Table 1). In the last of
these the monostotic left femur involvement was diagnosed
only through standard X-ray examination, so the possibility of
underestimation of skeletal involvement cannot be excluded
(Table 1). Over all, considering only the clinically ascertained
affected subjects (III-1, III-3, III-6, III-12 and III-13), the number
of bones involved in this family is 3.8 ± 2.31 (mean ± SD).
Three subjects in the family (II-3 (Fig. 2a), II-8 and II-10) were
presumably affected by PDB on the basis of the history related
by other members of the family and of the fact that progeny of
II-3 and II-8 carried the M404V mutation. In these three cases
the description of bone deformities was suggestive of multiple
bone localization.
Until now none of the unaffected members has exhibited AP
levels outside the normal range (that is, more than 120 units/l).
Mutational analysis
All the available ascertained affected PDB individuals from the
third generation (III-1, III-3, III-12 and III-13) exhibited the
M404V mutation of the p62/SQSTM1 gene (Table 1), con-
firming the pathogenetic nature of this p62/SQSTM1 gene
mutation and suggesting segregation of the mutation with the
polyostotic phenotype in this family. Although patient III-6 died
as a result of an osteogenic sarcoma on a Pagetic bone sev-
eral years before the genetic evaluation of F01 pedigree, he
probably had the M404V mutation. Through mutational
analysis the pedigree was carefully reconstructed, and this
allowed us to propose that patients II-1, II-2, II-3, II-7, II-8 and
III-5 were also carriers of the M404V mutation. In fact, their
PDB-affected children (III-1, III-3, III-6, III-12 and III-13) exhib-
ited the mutation (Table 1).
Of the unaffected subjects, II-6, III-7, III-8, III-9, III-10, III-14, III-
18, III-19, III-20, IV-2, IV-3, IV-5 and IV-6 (age range from 35 to
92 years) were not carrying the M404V p62/SQSTM1 gene
mutation, whereas subjects IV-1, IV-13, IV-14, IV-15 and IV-16
(age range from 41 to 53 years) were carrying the mutation
(Table 1).
Figure 2
Evidence of PDB in two affected subjects from F01 family Evidence of PDB in two affected subjects from F01 family. (a) Bone 
deformity of the right forearm of family member II-3. Relatives described 
him as having suffered from multiple bone deformities and pain. (b) X-
ray scan of the right tibia of family member III-3, with a typical flame-
shaped lytic wedge (arrow).Available online http://arthritis-research.com/content/7/6/R1289
R1293
AP levels were still in the normal range (less than 120 units/l)
in these gene carriers (Table 1).
Discussion
Several lines of evidence [2-7] support the role of the p62/
SQSTM1 gene in the pathogenesis of PDB, even though the
molecular mechanisms that underlie its functional activities are
not fully understood. Similarly, little information has been col-
lected about either the potential genotype–phenotype correla-
tion between gene mutations and clinical manifestations of
PDB [7] or the role of genetic testing in asymptomatic carriers
within affected families. The findings described in this paper
are of interest with regard to both issues.
The p62/SQSTM1 protein binds non-covalently to ubiquitin,
co-localizing with ubiquitinated inclusions in several human
diseases characterized by altered protein aggregation [10].
Moreover, the protein mediates several cellular functions
including NFκB-dependent signalling and transcriptional activ-
ity, which are important for the recruitment and activation of
osteoclastic cells [2].
The nuclear magnetic resonance structure of the p62-UBA
domain has recently been determined, but its functional signif-
icance in the p62 protein is still unknown [11]. The study by
Ciani and colleagues showed that the M404V mutation is able
to modify the secondary structure of the domain and affects its
ability to bind to Lys48-linked multiubiquitin chains in vitro [11].
Together with other p62/SQSTM1 gene mutations at the UBA
domain, Cavey and colleagues [12] showed that M404V is
able to cause the loss of monoubiquitin binding and impair in
vitro Lys48-linked polyubiquitin binding, although these effects
were reported only when the binding experiments were per-
formed at the physiological temperature of 37°C. These find-
ings suggest that PDB-related SQSTM1  mutations may
confer a higher susceptibility to development of the disease by
impairing the binding of the p62 protein to a ubiquitinated tar-
get. However, other molecular mechanisms, involving a key
ubiquitinated substrate, could be invoked in the attempt to
explain the acquisition of the PDB phenotype in individuals
with mutations of the p62/SQSTM1 gene [11]. A structural
analysis demonstrated in 4 of 70 PDB relatives with British
ancestry that an M404V mutation involves residues on the
hydrophobic surface patch implicated in ubiquitin binding [7].
Consequently, an M404V mutation affects the ability of a
mutant UBA domain to bind polyubiquitin chains [7].
Using this structural information Hocking and colleagues
reported that patients with truncating mutations of the p62/
SQSTM1 gene exhibited a trend for more extensive PDB than
those with mis-sense mutations such as M404V. They con-
cluded that there is no correlation between the ubiquitin-bind-
ing properties of different mutant UBA domains and disease
occurrence or extension of the same [7]. These findings there-
fore do not provide a speculative hypothesis for an explanation
of the observed genotype–phenotype correlation in the Italian
family with PDB described in this paper.
The heterozygous segregation of M404V mutation with the
PDB phenotype in the F01 pedigree supports the pathoge-
netic role via a dominant-negative action [4]. Moreover, the evi-
dence of a genotype–phenotype correlation in this family can
also include epigenetic mechanisms that, through a common
genetic background, can contribute, along with the M404V
mutation, to the expression of a polyostotic PDB phenotype in
the affected members. Interestingly, the commonly shared
rural environment of all the members from generations I to III
and, for a shorter period, generation IV of this family, together
with the presence of past measles infection in all individuals
analysed, could suggest a role for environmental factors in
determining the polyostotic expression of the disease in
M404V mutant subjects.
Clinical follow-up of asymptomatic carriers from generation IV
might confirm or negate this observation. Studies on the pen-
etrance of PDB have been performed by several authors [2-
4,9], the PDB shows an incomplete clinical expression, mean-
ing that some SQSTM1 gene carriers from affected families
do not show clinical evidence of the disease. Moreover, some
PDB-affected individuals, from affected families with a known
SQSTM1 gene mutation, do not exhibit the mutation [2-4,9].
Conversely, individuals older than 55 years of age with a
known SQSTM1 mutation from relatives affected with PDB,
did not develop PDB [4]. A potential explanation for these find-
ings is the existence of genetic heterogeneity, with possible
modifier loci capable of controlling the clinical expression of
PDB [4,9]. For individuals younger than 55 years of age with a
known SQSTM1 mutation, originating from relatives affected
with PDB, who had not yet developed PDB [4,8], the time
needed for phenotypic expression of the disease could repre-
sent a limiting factor. In general, a lack of expression of the dis-
ease in recognized SQSTM1 gene carriers could be explained
by a reduced exposure to environmental factors such as para-
mixovirus infections and/or by the progressive abandonment
of the rural environment [4,7].
An important application of genetic analyses in families is the
precocious identification of asymptomatic gene carriers. In this
relative the p62/SQSTM1 disease-associated mutation was
also present in individuals younger than 50 years of age [3,4].
So far the asymptomatic gene carriers have not exhibited any
abnormality in the circulating levels of AP and have not shown
any clinical signs suggestive of PDB. Although bone scanning
is commonly recommended in patients with PDB older than 40
years of age, because of the ethical considerations observed
in our country, bone scan tests cannot be performed unless
AP levels are raised and consequently PDB bone localization
cannot be excluded at this stage in asymptomatic mutant car-
riers. However, considering that a positive individual older thanArthritis Research & Therapy    Vol 7 No 6    Falchetti et al.
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40 years of age has an up to 80% likelihood of developing the
disease by 70 years of age [13], the extremely high pene-
trance of PDB in this family clearly indicates the need for an
accurate vertical follow-up of the six asymptomatic mutant car-
riers. This will allow us to confirm the suggested genotype–
phenotype correlation in the currently asymptomatic carriers
as well, and to assess the role of mutational analysis of the
p62/SQSTM1 gene for early detection of the individuals at risk
for developing PDB. At present, a positive test for the mutation
of the p62/SQSTM1 gene in a patient with PDB does not have
any impact on treatment [13].
Finally, one of the affected subjects (III-6) in this family devel-
oped an osteosarcoma that caused her death. Pagetoid oste-
osarcoma is a complication of PDB [14,15] and is most often
observed in severe, long-standing PDB. Two previous reports
described a direct lineage in which Pagetoid osteosarcoma
developed in affected family members [16,17]. Although spe-
cific genetic mechanisms remain to be elucidated, some
authors reported loss of heterozygosity for loci at chromosome
18q21-22 in Pagetoid osteosarcomas as well as in sporadic
osteosarcomas [17,18]. The deleted region was shown to har-
bour the receptor activator of nuclear factor κB (RANK,
TNFRSF11A) gene identified in a family affected by familial
expansile osteolysis (OMIM entry no. 174810), a Paget-like
syndrome [19]. Although the RANK gene has not been found
to be mutated in PDB-affected individuals, a positive associa-
tion between a polymorphic variant of this gene and PDB has
been reported [20,21]. NFκB is also the potential molecular
target of the mechanism underlying the altered osteoclas-
togenesis seen in PDB patients carrying mutated sequences
in the UBA domain of the p62/SQSTM1 gene [2-12]. Inactiva-
tion of the p62/SQSTM1  gene could activate the RANK–
NFκB signalling, as seen in the familial expansile osteolysis
syndrome [19], with impairment of TNF-α-induced pro-
grammed cell death [22]. Such machinery is also crucial for
immunity, lymphocyte development, tumorigenesis and cancer
chemoresistance; NFκB functions are recognized as relevant
to tumour promotion [23]. Even though the presence of the
M404V mutation could not be assessed in patient III-6, these
hypotheses strongly support the need for further investigation
into the possible role of the p62 protein in the occurrence of
osteosarcoma, both in PDB-affected patients and in individu-
als without PDB.
Conclusion
This paper describes a genotype–phenotype correlation in
PDB cases with a mis-sense mutation in the p62/SQSTM1
gene. These results should be confirmed in other PDB
patients of Italian and other ancestries. Moreover, the value of
a pre-symptomatic gene test in PDB requires a vertical evalu-
ation in well-characterized relatives, opening new possibilities
for the practical application of genetic diagnosis in PDB family
members and also in the general population. Finally, the knowl-
edge of the function of p62/SQSTM1 gene mutations should
enable us to uncover the pathogenesis of PDB and osteo-
genic osteosarcoma.
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